source
- Sarepta CEO Sees Path to Stronger DMD Trials Amid 2025 Elevidys SetbacksSarepta Therapeutics’ newly appointed chief executive Michael Severino, after a 90‑day assessment period, outlined a plan to restore the company’s leadership in the Duchenne muscular dystrophy mark…
- Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked NovemberAlso lined up are target action dates for Sanofi’s Gaucher disease therapy, GSK’s lung cancer medicine and BridgeBio’s muscular dystrophy drug.